Med BioGene reports pre-clinical results of its Diagnostic Lymphoma DNA Bioarray
Med BioGene Inc. announced the results of its pre-clinical studies involving its Diagnostic lymphoma Bioarray. The studies of fifty RNA samples derived from human lymphoma tissues suggest that MBI's Diagnostic Lymphoma Bioarray successfully differentiated between genes in both the diseased and healthy control samples.
Moreover, the results revealed a high dissimilarity between six lymphoma subtypes (Diffuse Large B-Cell, Mantle Cell, Follicular, Hodgkin, Marginal Zone and Small Lymphocytic) and the healthy control samples, indicating that the bioarray is able to detect differential expression profiles. The samples used in the studies did not include the subtype T-Cell Lymphoma; however, prior studies suggest that the bioarray is able to distinguish this subtype from healthy control samples. Sample replicates were also highly similar to one another, indicating a consistency in the bioarray.
Most read news
Other news from the department research and development
![Newsletter](https://img.chemie.de/assets/awportal/images/newsletter.png)
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.